心外膜脂肪组织与心血管疾病和代谢性疾病
吴昊, 白英, 邓可武 . 心外膜脂肪组织与心血管疾病和代谢性疾病[J]. 内科理论与实践, 2021 , 16(03) : 208 -211 . DOI: 10.16138/j.1673-6087.2021.03.015
| [1] | Salazar J, Luzardo E, Mejías JC, et al. Epicardial fat: physiological, pathological, and therapeutic implications[J]. Cardiol Res Pract, 2016, 2016: 1291537. |
| [2] | Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement[J]. Lancet Diabetes Endocrinol, 2019, 7(9): 715-725. |
| [3] | Villasante Fricke AC, Iacobellis G. Epicardial adipose tissue: clinical biomarker of cardio-metabolic risk[J]. Int J Mol Sci, 2019, 20(23): 5989. |
| [4] | Iacobellis G, Assael F, Ribaudo MC, et al. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction[J]. Obes Res, 2003, 11(2): 304-310. |
| [5] | Rabkin SW. The relationship between epicardial fat and indices of obesity and the metabolic syndrome: a systematic review and meta-analysis[J]. Metab Syndr Relat Disord, 2014, 12(1): 31-42. |
| [6] | Ansari MA, Mohebati M, Poursadegh F, et al. Is echocardiographic epicardial fat thickness increased in patients with coronary artery disease? A systematic review and meta-analysis[J]. Electron Physician, 2018, 10(9): 7249-7258. |
| [7] | Bachar GN, Dicker D, Kornowski R, et al. Epicardial adipose tissue as a predictor of coronary artery disease in asymptomatic subjects[J]. Am J Cardiol, 2012, 110(4): 534-538. |
| [8] | Toya T, Corban MT, Imamura K, et al. Coronary perivascular epicardial adipose tissue and major adverse cardiovascular events after ST segment-elevation myocardial infarction[J]. Atherosclerosis, 2020, 302: 27-35. |
| [9] | Al Chekakie MO, Welles CC, Metoyer R, et al. Pericardial fat is independently associated with human atrial fibrillation[J]. J Am Coll Cardiol, 2010, 56(10): 784-788. |
| [10] | Gaeta M, Bandera F, Tassinari F, et al. Is epicardial fat depot associated with atrial fibrillation[J]?. Europace, 2017, 19(5): 747-752. |
| [11] | Sepehri Shamloo A, Dagres N, Dinov B, et al. Is epicardial fat tissue associated with atrial fibrillation recurrence after ablation[J]?. Int J Cardiol Heart Vasc, 2019, 22: 132-138. |
| [12] | Erdogan G, Belen E, Sungur MA, et al. Assessment of epicardial adipose tissue thickness in patients with resistant hypertension[J]. Blood Press Monit, 2016, 21(1): 16-20. |
| [13] | Song Y, Song F, Wu C, et al. The roles of epicardial adipose tissue in heart failure[J]. Heart Fail Rev, 2020. [Epub ahead of print]. |
| [14] | Koepp KE, Obokata M, Reddy YNV, et al. Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction[J]. JACC Heart Fail, 2020, 8(8): 657-666. |
| [15] | van Woerden G, Gorter TM, Westenbrink BD, et al. Epicardial fat in heart failure patients with mid-range and preserved ejection fraction[J]. Eur J Heart Fail, 2018, 20(11): 1559-1566. |
| [16] | Li Y, Liu B, Li Y, et al. Epicardial fat tissue in patients with diabetes mellitus: a systematic review and meta-analysis[J]. Cardiovasc Diabetol, 2019, 18(1): 3. |
| [17] | Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features[J]. Trends Endocrinol Metab, 2011, 22(11): 450-457. |
| [18] | Sayin I, Erkan AF, Ekici B, et al. Thickening of the epicardial adipose tissue can be alleviated by thyroid hormone replacement therapy in patients with subclinical hypothyroidism[J]. Kardiol Pol, 2016, 74(12): 1492-1498. |
| [19] | 王怡文, 王侃侃, 宋玉玲, 等. 亚临床甲状腺功能减退症与心外膜脂肪组织厚度相关性的Meta分析[J]. 滨州医学院学报, 2019, 42(3): 188-212. |
| [20] | Altunbaş R, Eren MA, Altıparmak IH, et al. The relation between epicardial fat tissue thickness and TSH receptor antibody in hyperthyroidism[J]. Exp Clin Endocrinol Diabetes, 2019, 127(1): 37-40. |
| [21] | Liu B, Li Y, Li Y, et al. Association of epicardial adipose tissue with non-alcoholic fatty liver disease: a meta-analysis[J]. Hepatol Int, 2019, 13(6): 757-765. |
| [22] | Meng X, Wang W, Zhang K, et al. Epicardial adipose tissue volume is associated with non-alcoholic fatty liver disease and cardiovascular risk factors in the general population[J]. Ther Clin Risk Manag, 2018, 14: 1499-1506. |
| [23] | Lin A, Wong ND, Razipour A, et al. Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study[J]. Cardiovasc Diabetol, 2021, 20(1): 27. |
| [24] | Chacińska M, Zabielski P, Ksiazek M, et al. The impact of OMEGA-3 fatty acids supplementation on insulin resistance and content of adipocytokines and biologically active lipids in adipose tissue of high-fat diet fed rats[J]. Nutrients, 2019, 11(4): 835. |
| [25] | Ziyrek M, Kahraman S, Ozdemir E, et al. Metformin monotherapy significantly decreases epicardial adipose tissue thickness in newly diagnosed type 2 diabetes patients[J]. Rev Port Cardiol, 2019, 38(6): 419-423. |
| [26] | Grosso AF, de Oliveira SF, Higuchi Mde L, et al. Synergistic anti-inflammatory effect: simvastatin and pioglitazone reduce inflammatory markers of plasma and epicardial adipose tissue of coronary patients with metabolic syndrome[J]. Diabetol Metab Syndr, 2014, 6(1): 47. |
| [27] | Iacobellis G, Mohseni M, Bianco SD, et al. Liraglutide causes large and rapid epicardial fat reduction[J]. Obesity (Silver Spring), 2017, 25(2): 311-316. |
| [28] | Bizino MB, Jazet IM, de Heer P, et al. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation[J]. Diabetologia, 2020, 63(1): 65-74. |
| [29] | Braha A, Timar B, Diaconu L, et al. Dynamics of epicardiac fat and heart function in type 2 diabetic patients initiated with SGLT-2 inhibitors[J]. Diabetes Metab Syndr Obes, 2019, 12: 2559-2566. |
| [30] | Parisi V, Petraglia L, D'Esposito V, et al. Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue[J]. Int J Cardiol, 2019, 274: 326-330. |
| [31] | Launbo N, Zobel EH, von Scholten BJ, et al. Targeting epicardial adipose tissue with exercise, diet, bariatric surgery or pharmaceutical interventions[J]. Obes Rev, 2021, 22(1): e13136. |
/
| 〈 |
|
〉 |
